Understanding ELN-2022 Favorable-Risk AML and Genetic Nuances

The 2022 European Leukemia Net (ELN) guidelines have transformed the way clinicians approach ELN-2022 favorable-risk AML. While myelodysplasia-related gene (MRG) mutations are typically markers of adverse prognosis, their impact on patients within the favorable-risk category has remained unclear. A recent cohort study involving 221 adult patients has shed light on this specific clinical scenario. The results suggest that the number of mutations, rather than just their presence, is the critical factor for determining long-term outcomes. Hematologists in India and abroad must now look beyond binary detection to understand patient risk better.

Quantifying MRG Mutations in ELN-2022 Favorable-Risk AML

The study found that approximately 21.3% of patients with favorable-risk AML carried at least one MRG mutation. These mutations, which include genes like ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2, were more common in older patients. Furthermore, they were frequently associated with lower white blood cell counts and specific co-mutations such as TET2 and MPL. Interestingly, the presence of a single MRG mutation did not significantly reduce 2-year overall survival or leukemia-free survival (LFS) in this group. Therefore, a lone mutation may not always warrant a shift to intensive adverse-risk protocols.

Impact of High Mutation Burden on Patient Prognosis

However, a different story emerged when researchers analyzed patients with multiple mutations. Those with a high MRG mutation burden—defined as two or more mutations—faced a significantly poorer LFS compared to those with one or no mutations. Multivariable analysis confirmed that harboring ≥2 MRG mutations is an independent predictor of worse survival outcomes. Consequently, hematologists should prioritize quantifying mutation burden to refine risk stratification and treatment planning. This finding emphasizes the need for comprehensive next-generation sequencing in routine clinical practice.

What are the common MRG mutations in AML?

The primary myelodysplasia-related genes (MRG) include ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2. These are typically associated with an adverse prognosis according to ELN-2022 guidelines unless specific favorable lesions are present.

How many mutations are needed to change the prognosis in favorable-risk patients?

While a single MRG mutation does not appear to worsen outcomes in ELN-2022 favorable-risk AML, the presence of two or more MRG mutations is independently associated with significantly poorer leukemia-free survival (LFS).

Does a single MRG mutation require changing the treatment plan in favorable-risk AML?

Based on this recent evidence, a single MRG mutation does not necessarily confer a worse prognosis in the favorable-risk group. However, clinicians should monitor the total mutation burden closely, as a higher burden (≥2 mutations) signals a higher risk of relapse.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the provider. Always seek the advice of a qualified healthcare professional for any medical concerns. Refer to the latest local and national guidelines for clinical practice.

References

Zhang L et al. Prognostic impact of myelodysplasia-related gene mutations in ELN-2022 favorable-risk acute myeloid leukemia subtypes. Ann Med. 2026 Dec undefined. doi: 10.1080/07853890.2026.2636337. PMID: 41797681.

Döhner H et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377.

Mecklenbrauck R et al. Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia. Leukemia. 2026 Feb. doi: 10.1038/s41375-025-02456-x.